Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 14/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ARNT | P27540 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573899 | 1.00 | PIK3CA (0.38) | PIK3CACISD1P2RX7KDM4EARNT | |
| SCHEMBL5573274 | 0.88 | ALDH1A1 (0.37) | KDM4E | |
| SCHEMBL5571290 | 0.88 | ALDH1A1 (0.37) | KDM4E | |
| SCHEMBL5571297 | 0.85 | GRM4 (0.41) | CISD1P2RX7 | |
| SCHEMBL5571291 | 0.85 | GRM4 (0.41) | CISD1P2RX7 | |
| SCHEMBL3371424 | 0.84 | P2RX7 (0.35) | CISD1P2RX7ARNTEPAS1 | |
| SCHEMBL13069299 | 0.84 | P2RX7 (0.35) | CISD1P2RX7ARNTEPAS1 | |
| SCHEMBL3370868 | 0.84 | P2RX7 (0.35) | CISD1P2RX7ARNTEPAS1 | |
| SCHEMBL3372531 | 0.81 | CISD1 (0.37) | CISD1ARNTEPAS1 | |
| SCHEMBL3372536 | 0.81 | CISD1 (0.37) | CISD1ARNTEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268231-B2 | 1,5-Naphthyridine azolinone | HOFFMANN-LA ROCHE INC. (US) | 2007-09-11 | — | — | US | claimed |
| EP-1805174-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-07-11 | — | — | EP | claimed |
| WO-2006040052-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | claimed |
| US-20060084673-A1 | 1,5-naphthyridine azolinone | LIU JIN-JUN | 2006-04-20 | — | — | US | claimed |
| US-7268231-B2 | 1,5-Naphthyridine azolinone | HOFFMANN-LA ROCHE INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1805174-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040052-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060084673-A1 | 1,5-naphthyridine azolinone | LIU JIN-JUN | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084673-A1 | 1,5-naphthyridine azolinone | CDK1, CDK15, CDK14 | PIK3CA 448/4885CISD1 1341/4885P2RX7 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.